Tests a new outpatient care model for people with heart failure
Studies whether a new clinic-based follow-up service helps adults with heart failure after hospital discharge.
Plain-language title generated from the registry record
Registry title: Ambulatory Heart Failure Service Model Study
Key facts
- Where
- Shatin, Hong KongSee the site
Where in Hong Kong
- The Chinese University of Hong KongShatin, Hong KongNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Chinese University of Hong Kong
- Trial code
- NCT05556031
- Record updated
- 27 September 2022
- Original description
The aim of the study is to assess the efficacy of this new ambulatory service model in reducing heart failure hospitalization (HHF), improving clinical as well as functional outcomes of post-discharge patients with Heart Failure of reduced ejection fraction (HFrEF) and Heart failure with preserved Ejection Fraction (HFpEF).Read full original descriptionShow less
The Reduction of Decompensation and Unnecessary Cardiac Failure Emergency Admissions: Ambulatory Heart Failure Service Model
The aim of the study is to assess the efficacy of this new ambulatory service model in reducing heart failure hospitalization (HHF), improving clinical as well as functional outcomes of post-discharge patients with Heart Failure of reduced ejection fraction (HFrEF) and Heart failure with preserved Ejection Fraction (HFpEF).
Inclusion: Dyspnoea (exertional or at rest) and 2 of the following signs:; Congestion on chest X-ray; Rales on chest auscultation; Clinically relevant oedema (e.g. ≥1+ on a 0 to 3+ scale); Elevated jugular venous pressure; NT-proBNP ≥300 pg/mL (Patients with AF: NT-proBNP ≥900 pg/mL); Heart failure hospitalization that requires the treatment of a minimum single dose of 40 mg of i.v. furosemide (or equivalent i.v loop diuretics); Ambulatory patients.
Exclusion: Cardiac mechanical support implantation like LVAD; Life expectancy less than 1 year due to underlying significant comorbidities like metastatic cancer or end-stage COPD; Haemodynamically severe uncorrected primary cardiac valvular disease planned for surgery or intervention during the course of the study; End stage renal failure or eGFR <15 mL/min/1.73m2 as measured during index hospitalization or requiring dialysis; Cardiogenic shock required inotropics.